Eli Lilly and Company (NYSE:LLY) Shares Sold by Bank OZK

Bank OZK lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,801 shares of the company’s stock after selling 451 shares during the period. Eli Lilly and Company accounts for approximately 3.4% of Bank OZK’s portfolio, making the stock its 3rd largest position. Bank OZK’s holdings in Eli Lilly and Company were worth $6,879,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. International Assets Investment Management LLC boosted its stake in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. Sapient Capital LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at $617,312,000. J.P. Morgan Private Wealth Advisors LLC acquired a new position in Eli Lilly and Company in the third quarter valued at $435,736,000. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Eli Lilly and Company by 24.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after acquiring an additional 645,473 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on LLY shares. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Truist Financial reaffirmed a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a report on Monday, April 15th. Finally, JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $8.64 during mid-day trading on Friday, reaching $733.51. The company had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. Eli Lilly and Company has a 1 year low of $380.77 and a 1 year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company has a market capitalization of $696.95 billion, a P/E ratio of 126.47, a P/E/G ratio of 1.58 and a beta of 0.34. The stock’s 50-day simple moving average is $761.79 and its 200-day simple moving average is $666.06.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the company posted $2.09 earnings per share. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, equities analysts predict that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.